AllSci News
Pfizer terminates Phase I trial of anti-CD25 ADC PF-08046032 in oncology
Pfizer's Phase I program for PF-08046032, an anti-CD25 antibody-drug conjugate designed to deplete immunosuppressive regulatory T cells within the tumor...
Restore Vision's optogenetic gene therapy restores light perception in end-stage retinitis pigmentosa patients
Interim data from a GPCR-based optogenetic gene therapy add early human evidence to a mutation-agnostic approach for end-stage retinitis pigmentosa, a...
CDT Equity advances patent strategy for AZ-acquired myeloperoxidase inhibitor for male infertility
CDT Equity Inc. (Nasdaq: CDT), headquartered in Naples, Florida, has advanced AZD5904, a selective myeloperoxidase (MPO) inhibitor originally licensed from AstraZeneca, into…
European Commission approves Pfizer’s Hympavzi for hemophilia A and B patients with inhibitors
The European Commission has approved Pfizer’s Hympavzi (marstacimab) for hemophilia A and B patients with inhibitors. The approval means Pfizer is one…
PharmAla Biotech forms Restora Neurosciences SPV with Aluvaris for MDXX clinical development
PharmAla Biotech (CSE: MDMA; OTCQB: MDXXF), Toronto, has structured a special purpose vehicle to advance APA-01, a patented pre-IND MDXX-class small...
Whitehawk Therapeutics raises USD 87.5m in private placement to extend ADC runway through 2028
A clinical-stage antibody drug conjugate company is extending its cash runway into the second half of 2028 through a USD 87.5 million private placement,...
Actuate Therapeutics' oral GSK-3β inhibitor elraglusib set for first trials in advanced solid tumors
A shift from intravenous to oral administration marks the next phase of Actuate Therapeutics' (Nasdaq: ACTU) elraglusib program, after the Chicago- and Fort...
Delos Capital and AP Biosciences launch venture creation platform for next-generation antibodies
A venture creation model combining biologics discovery with company-building infrastructure positions AP Biosciences to extend its antibody platforms beyond its internal pipeline,…
AndzonBio2 taps up Cambridge Uni’s ALBORADA institute for neuroinflammatory drug discovery
A Paris-based neuroscience company is gaining access to one of the UK’s leading academic drug discovery platforms, focused on neuroinflammation as a…
Collegium acquires Azstarys from Corium Therapeutics for USD 650m plus contingent payments
Collegium Pharmaceutical (Nasdaq: COLL), headquartered in Stoughton, Massachusetts, has completed the acquisition of Azstarys (serdexmethylphenidate and...
Akari Therapeutics secures European patent for Thailanstatin analog ADC payload platform
A European composition-of-matter patent covering a novel class of RNA splicing modulator payloads extends intellectual property protection for Akari Therapeutics’ antibody-drug conjugate…
Oxcia AB secures Canadian patent for OXC-201 ahead of Phase I in IPF
Oxcia AB (Sweden), a clinical-stage company focused on oxidative DNA damage and DNA Damage Response (DDR) biology, has received Canadian patent approval…
Azitra secures US patent for ATR-12 engineered microbiome therapy targeting Netherton syndrome
A new US patent covering an engineered live biotherapeutic for Netherton syndrome was awarded to Connecticut-based Azitra, Inc. (NYSE American: AZTR). As…
Catalyst Pharmaceuticals resolves final US patent litigation, securing FIRDAPSE market exclusivity through January 2035
A negotiated patent settlement on Firdapse (amifampridine) between Catalyst Pharmaceuticals and Hetero Labs Ltd. has closed the last open front in amifampridine…
Rigel acquires Veppanu from Arvinas and Pfizer for USD 85m upfront
Rigel Pharmaceuticals (Nasdaq: RIGL) is acquiring exclusive global rights to Veppanu (vepdegestrant), the first US FDA-approved oral PROTAC, in a deal that...
The AllSci Brief
Systematic R&D and deal news. Daily.